nach oben

Diabetologia

Erschienen in:

01.03.2007 | Article

Adenoviral overproduction of interleukin-1 receptor antagonist increases beta cell replication and mass in syngeneically transplanted islets, and improves metabolic outcome

verfasst von: N. Téllez, M. Montolio, E. Estil·les, J. Escoriza, J. Soler, E. Montanya

Erschienen in: Diabetologia | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Interleukin-1 receptor antagonist (IL1RN, also known as IL1RA) is a naturally occurring inhibitor of IL-1 action and its overproduction protects pancreatic islets from the deleterious effects of IL-1β on beta cell replication, apoptosis and function. The aim of this study was to determine whether viral gene transfer of the Il1rn gene into rat islets ex vivo had a beneficial effect on the outcome of the graft.

Materials and methods

Streptozotocin-diabetic Lewis rats were syngeneically transplanted with 500 or 800 Ad-Il1rn-infected or uninfected islets. Islet grafts were collected on day 3, 10 or 28 after transplantation and beta cell apoptosis, replication, size and mass were determined.

Results

Animals transplanted with 500 islets remained hyperglycaemic throughout the follow-up, as expected. Beta cell replication increased in the Ad-Il1rn group on days 3, 10 and 28 after transplantation compared with normal pancreas. In uninfected islets, by contrast, beta cell replication was increased only on day 10. Beta cell apoptosis was increased in all transplanted groups; it was 25% lower in the Ad-Il1rn than in uninfected groups, but differences were not statistically significant. The initially transplanted beta cell mass was reduced on day 3, increasing subsequently in Ad-Il1rn grafts, but not in uninfected grafts. When 800 islets were transplanted, all animals grafted with Ad-Il1rn-infected islets, but only 40% of those transplanted with uninfected islets, achieved normoglycaemia 14 days after transplantation.

Conclusions/interpretation

Overproduction of IL1RN increased beta cell replication and mass of islet grafts and reduced the beta cell number required to achieve normoglycaemia.

Nur mit Berechtigung zugänglich

Davalli A, Scaglia L, Zangen D, Hollister J, Bonner-Weir S, Weir GC (1996) Vulnerability of islets in the immediate posttransplantation period: dynamic changes in structure and function. Diabetes 45:1161–1167PubMed

Biarnés M, Montolio M, Nacher V, Raurell M, Soler J, Montanya E (2002) Beta cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycaemia. Diabetes 51:66–72PubMed

Kaufman DB, Morel P, Field MJ, Munn SR, Sutherland DE (1990) Purified canine islet autografts. Functional outcome as influenced by islet number and implantation site. Transplantation 50:385–391PubMedCrossRef

Vargas F, Vives-Pi M, Somoza N et al (1998) Endotoxin contamination may be responsible for the unexplained failure of human pancreatic islet transplantation. Transplantation 65:722–727PubMedCrossRef

Rosenberg L, Wang R, Paraskevas S, Maysinger D (1999) Structural and functional changes resulting from islet isolation lead to islet cell death. Surgery 126:393–398PubMed

Kaufman DB, Rabe F, Platt JL, Stock PG, Sutherland DER (1988) On the variability of outcome after islet allotransplantation. Transplantation 45:1151–1153PubMedCrossRef

Montaña E, Bonner-Weir S, Weir GC (1993) Beta cell mass and growth after syngeneic islet cell transplantation in normal and streptozocin diabetic C57BL/6 mice. J Clin Invest 91:780–787PubMed

Dionne KE, Colton CK, Yarmush ML (1993) Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. Diabetes 42:12–21PubMed

Merino JF, Nacher V, Raurell M, Aranda O, Soler J, Montanya E (1997) Improved outcome of islet transplantation in insulin-treated diabetic mice: effects on beta cell mass and function. Diabetologia 40:1004–1010PubMedCrossRef

10.

Ilieva A, Yuan S, Wang RN, Agapitos D, Hill DJ, Rosenberg L (1999) Pancreatic islet cell survival following islet isolation: the role of cellular interactions in the pancreas. J Endocrinol 161:357–364PubMedCrossRef

11.

Thomas FT, Contreras JL, Bilbao G, Ricordi C, Curiel D, Thomas JM (1999) Anoikis, extracellular matrix, and apoptosis factors in isolated islet transplantation. Surgery 126:299–304PubMed

12.

Berney T, Molano RD, Cattan P et al (2001) Endotoxin-mediated delayed islet graft function is associated with increased intra-islet cytokine production and islet cell apoptosis. Transplantation 71:125–132PubMedCrossRef

13.

Ozasa T, Newton MR, Dallman MJ, Shimizu S, Gray DW, Morris PJ (1997) Cytokine gene expression in pancreatic islet grafts in the rat. Transplantation 64:1152–1159PubMedCrossRef

14.

Montolio M, Biarnés M, Téllez N, Escoriza J, Soler J, Montanya E. IL-1beta and iNOS expression in early syngeneic islet transplantation. J Endocrinol, in press

15.

Téllez N, Montolio M, Biarnés M, Castaño E, Soler J, Montanya E (2005) Adenoviral overexpression of interleukin-1 receptor antagonist protein increases beta cell replication in rat pancreatic islets. Gene Ther 12:120–128PubMedCrossRef

16.

Rabinovitch A (1998) An update on cytokines in the pathogenesis of insulin dependent diabetes mellitus. Diabetes/Metab Rev 14:129–151CrossRef

17.

Mandrup-Poulsen T (1996) The role of interleukin-1 in the pathogenesis of insulin-dependent diabetes mellitus. Diabetologia 39:1005–1029PubMed

18.

Scarim AL, Arnush M, Hill JR et al (1997) Evidence for the presence of type I IL-1 receptors on beta cells of islets of Langerhans. Biochim Biophys Acta 1361:313–320PubMed

19.

Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP (1991) Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 266:10331–10336PubMed

20.

Giannoukakis N, Rudert WA, Ghivizzani SC et al (1999) Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1β-induced beta cell impairment and activation of islet cell apoptosis in vitro. Diabetes 48:1730–1736PubMed

21.

Sandberg JO, Eizirik DL, Sandler S (1997) IL-1 receptor antagonist inhibits recurrence of disease after syngenic pancreatic islet transplantation to spontaneously diabetic non-obese (NOD) mice. Clin Exp Immunol 108:314–317PubMedCrossRef

22.

Sandberg JO, Andersson A, Eizirik DL, Sandler S (1994) Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice. Biochem Biophys Res Commun 202:543–548PubMedCrossRef

23.

Sandberg JO, Eizirik DL, Sandler S, Tracey DE, Andersson A (1993) Treatment with an interleukin-1 receptor antagonist protein prolongs mouse islet allograft survival. Diabetes 42:1845–1851PubMed

24.

Bell RC, Khurana M, Ryan EA, Finegood DT (1994) Gender differences in the metabolic response to graded numbers of transplanted islets of Langerhans. Endocrinology 135:2681–2687PubMedCrossRef

25.

Nacher V, Raurell M, Merino JF, Aranda O, Soler J, Montana E (1996) Beta cell growth and mass are preserved in long-term syngeneic islet transplantation in streptozocin-induced diabetic Lewis rats. Diabetes 45:1541–1546PubMed

26.

Maedler K, Sergeev P, Ehses JA et al (2004) Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci USA 101:8138–8143PubMedCrossRef

27.

Weibel ER (1979) Point counting methods. In: Weibel ER (ed) Sterological methods, vol 1. Academic, London, pp 101–161

28.

Arnush M, Scarim AL, Heitmeier MR, Kelly CB, Corbett JA (1998) Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes. J Immunol 160:2684–2691PubMed

29.

Ryan EA, Lakey JR, Rajotte RV et al (2001) Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 50:710–719PubMed

30.

Swenne I (1982) The role of glucose in the in vitro regulation of cell cycle kinetics and proliferation of fetal pancreatic beta cells. Diabetes 31:754–760PubMed

31.

Bonner-Weir S, Deery D, Leahy JL, Weir GC (1989) Compensatory growth of pancreatic beta cells in adult rats after short-term glucose infusion. Diabetes 38:49–53PubMed

32.

Nacher V, Merino JF, Raurell M, Soler E, Montanya E (1998) Normoglycaemia restores beta cell replicative response to glucose in transplanted islets exposed to chronic hyperglycaemia. Diabetes 47:192–196PubMed

33.

Welsh N, Cnop M, Kharroubi I et al (2005) Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or type 2 diabetes milieu to human pancreatic islets? Diabetes 54:3238–3244PubMed

34.

Maedler K, Sergeev P, Ris F et al (2002) Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851–860PubMedCrossRef

35.

Montana E, Bonner-Weir S, Weir GC (1994) Transplanted beta cell response to increased metabolic demand. Changes in beta cell replication and mass. J Clin Invest 93:1577–1582PubMedCrossRef

36.

Benhamou PY, Moriscot C, Richard MJ et al (1998) Adenovirus-mediated catalase gene transfer reduces oxidant stress in human, porcine and rat pancreatic islets. Diabetologia 41:1093–1100PubMedCrossRef

37.

Muruve DA, Manfro RC, Strom TB, Libermann TA (1997) Ex vivo adenovirus-mediated gene delivery leads to long-term expression in pancreatic islet transplants. Transplantation 64:542–546PubMedCrossRef

38.

Garcia-Ocaña A, Takane KK, Reddy VT, Lopez-Talavera JC, Vasavada RC, Stewart AF (2003) Adenovirus-mediated hepatocyte growth factor expression in mouse islets improves pancreatic transplant performance and reduces beta cell death. J Biol Biochem 278:343–351CrossRef

39.

Contreras JL, Bilbao G, Smyth CA et al (2002) Cytoprotection of pancreatic islets before and early after transplantation using gene therapy. Kidney Int 61(Suppl 1):79–84PubMedCrossRef

40.

Contreras JL, Bilbao G, Smyth CA et al (2001) Gene transfer of the Bcl-2 gene confers cytoprotection to isolated adult porcine pancreatic islets exposed to xenoreactive antibodies and complement. Surgery 130:166–174PubMedCrossRef

41.

Grey ST, Longo C, Shukri T et al (2003) Genetic engineering of a suboptimal islet graft with A20 preserves β cell mass and function. J Immunol 170:6250–6256PubMed

42.

Li X, Chen H, Epstein PN (2004) Metallothionein protects islets from hypoxia and extends islet graft survival by scavenging most kinds of reactive oxygen species. J Biol Chem 279:765–771PubMedCrossRef

43.

Lopez-Talavera JC, Garcia-Ocaña A, Sipula I, Takane KK, Cozar-Castellano, Stewart A (2004) Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplant. Endocrinology 145:467–474PubMedCrossRef

44.

Rao P, Roccisana J, Takane KK et al (2005) Gene transfer of constitutively active Akt markedly improves human islet transplant outcomes in diabetic severe combined immunodeficient mice. Diabetes 54:1664–1675PubMed

45.

Donath MY, Faulenbach M, Larsen CM, Vaag A, Mandrup-Poulsen T (2006) Treatment with interleukin-1 receptor antagonist improves glycaemic control and α-cell function in patients with type 2 diabetes mellitus. Diabetologia 49(Suppl 1):AO253 (Abstract)

Titel: Adenoviral overproduction of interleukin-1 receptor antagonist increases beta cell replication and mass in syngeneically transplanted islets, and improves metabolic outcome
verfasst von: N. Téllez
M. Montolio
E. Estil·les
J. Escoriza
J. Soler
E. Montanya
Publikationsdatum: 01.03.2007
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 3/2007
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-006-0548-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Materials and methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2007

Post-translational protein modifications in type 1 diabetes: a role for the repair enzyme protein-l-isoaspartate (d-aspartate) O-methyltransferase?

Adiponectin receptor genes: mutation screening in syndromes of insulin resistance and association studies for type 2 diabetes and metabolic traits in UK populations

A. Veves, J.M. Giurini, F.W. LoGerfo (eds) The diabetic foot (second edn). Humana Press, Totowa, New Jersey, 2006

Expression of the gene encoding the high-K m glucose transporter 2 by the early postimplantation mouse embryo is essential for neural tube defects associated with diabetic embryopathy

Activation of c-Jun NH2-terminal kinase (JNK) pathway during islet transplantation and prevention of islet graft loss by intraportal injection of JNK inhibitor